Antril human recombinant interleukin-1 receptor antagonist data

At a symposium of the Society of Critical Care Medicine, the Boulder, Colo., company presented an analysis of its Phase III study, showing increased survival time over 28 days in a subgroup of patients with more than one organ involved, for the higher dose of IL-1ra tested. ...